Pipeline overview

 

We are advancing a broad pipeline of proprietary  and partnered assets, including six clinical and several preclinical peptide drug candidates.

Our pipeline reflects our therapeutic focus on cardio-metabolic diseases. All peptide medicines in our pipeline are invented in-house.